David Cordani, Chairman and CEO of The Cigna Group (NASDAQ:CI), was involved in substantial equity transactions on May 12 and May 13, 2026. According to a recent Form 4 filing with the Securities and Exchange Commission, these activities included both the disposition of common stock valued at roughly $59.1 million and the acquisition of shares amounting to approximately $36.2 million.
It is important to note that all reported trading actions were executed under the framework of a pre-arranged Rule 10b5-1 trading plan, which was initially adopted on February 6, 2026. This structure suggests adherence to established guidelines for managing insider transactions.
Contextual Market Data and Valuation
At the time of these filings, Cigna shares were trading at $294.93. The healthcare company maintains a substantial market capitalization of $78.1 billion. From an analytical perspective, the stock's valuation has been highlighted as potentially undervalued by InvestingPro analysis, which placed it on a list of companies deemed highly undervalued based on its Fair Value assessment.
While Cigna has achieved a year-to-date return approaching 10%, the current price remains considerably lower than its peak within the last 52 weeks. The high point for CI was recorded at $338.89, indicating a notable distance from recent trading levels.
Details of Stock Disposition and Acquisition
Stock Sales (Disposition)
Mr. Cordani disposed of a total quantity of 191,549 shares of Cigna Group common stock. These sales occurred at weighted average prices ranging from $286.832 to $298.5328 per share, resulting in an aggregate value of approximately $59,114,186.
The reported selling prices represent weighted averages; consequently, the actual prices received for individual units sold varied within specific ranges.
Stock Purchases (Acquisition)
Conversely, Mr. Cordani acquired a total of 212,543 shares of Cigna Group common stock. These purchases totaled approximately $36,205,220. The acquisition prices for these shares fluctuated between $149.135 and $197.35 per share.
These acquired shares were obtained through the exercise of employee stock options. Specifically, the options exercised on May 12 and May 13, 2026, had original grant dates of February 28, 2017, and February 28, 2018, respectively. Furthermore, these option grants were structured to vest in three equal annual installments.
Financial Health and Analyst Ratings
Company Fundamentals
The financial profile of Cigna Group continues to demonstrate resilience. The company reported revenue of $277.89 billion over the preceding twelve months, as measured up to Q1 2026. Additionally, diluted earnings per share reached $23.60.
An assessment from InvestingPro points out that Cigna is trading at a low Price-to-Earnings (P/E) ratio of 12.5 when compared against near-term earnings growth. Furthermore, the platform assigned an attractive PEG ratio of 0.38 to the stock. The overall financial health was rated by the platform as